E-Learning

(Bloomberg) -- Emerging markets were swept up in the global equities storm Friday, with Asian stocks taking the heaviest beating after President Donald Trump’s latest tariff threats.Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC Office Buildings See Resurgence as Investors Pile Into BondsNYC’s Congestion Pricing Pulls In $48.6

Deborah Elms, head of trade policy for the Hinrich Foundation, said: “I do not know anyone who anticipated another 10% tariff against China so soon."

(Bloomberg) -- Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here.Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC Office Buildings See Resurgence as Investors Pile Into BondsNYC’s Congestion Pricing Pulls In $48.6 Million in First MonthIndia’

European markets were in the red on Friday morning after China vowed to retaliate as necessary to Donald Trump's extra 10% tariff hike.View on euronews

The answer depends on your goals, risk tolerance, current asset allocation.

Over the past six months, Revvity’s shares (currently trading at $111) have posted a disappointing 8.5% loss, well below the S&P 500’s 5.1% gain. This was partly due to its softer quarterly results and might have investors contemplating their next move.

Over the past six months, BD’s shares (currently trading at $224.85) have posted a disappointing 5.9% loss, well below the S&P 500’s 5.1% gain. This might have investors contemplating their next move.

RH’s 23.3% return over the past six months has outpaced the S&P 500 by 18.2%, and its stock price has climbed to $329.50 per share. This run-up might have investors contemplating their next move.

AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%.

Schneider has been treading water for the past six months, recording a small loss of 3.3% while holding steady at $26.09. The stock also fell short of the S&P 500’s 5.1% gain during that period.